» Articles » PMID: 27339249

Nonsteroidal Anti-Inflammatory Drug Without Antibiotics for Acute Viral Infection Increases the Empyema Risk in Children: A Matched Case-Control Study

Overview
Journal J Pediatr
Specialty Pediatrics
Date 2016 Jun 25
PMID 27339249
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the risk factors of empyema after acute viral infection and to clarify the hypothesized association(s) between empyema and some viruses and/or the use of nonsteroidal anti-inflammatory drugs (NSAIDs).

Study Design: A case-control study was conducted in 15 centers. Cases and controls were enrolled for a source population of children 3-15 years of age with acute viral infections between 2006 and 2009.

Results: Among 215 empyemas, 83 cases (children with empyema and acute viral infection within the 15 preceding days) were included, and 83 controls (children with acute viral infection) were matched to cases. Considering the intake of any drug within 72 hours after acute viral infection onset and at least 6 consecutive days of antibiotic use and at least 1 day of NSAIDs exposure, the multivariable analysis retained an increased risk of empyema associated with NSAIDs exposure (aOR 2.79, 95% CI 1.4-5.58, P = .004), and a decreased risk associated with antibiotic use (aOR 0.32, 95% CI 0.11-0.97, P = .04). The risk of empyema associated with NSAIDs exposure was greater for children not prescribed an antibiotic and antibiotic intake diminished that risk for children given NSAIDs.

Conclusions: NSAIDs use during acute viral infection is associated with an increased risk of empyema in children, and antibiotics are associated with a decreased risk. The presence of antibiotic-NSAIDs interaction with this risk is suggested. These findings suggest that NSAIDs should not be recommended as a first-line antipyretic treatment during acute viral infections in children.

Citing Articles

Post-resolution macrophages shape long-term tissue immunity and integrity in a mouse model of pneumococcal pneumonia.

Feehan K, Bridgewater H, Stenkiewicz-Witeska J, De Maeyer R, Ferguson J, Mack M Nat Commun. 2024; 15(1):4326.

PMID: 38773113 PMC: 11109210. DOI: 10.1038/s41467-024-48138-y.


Causal effects and immune cell mediators between prescription analgesic use and risk of infectious diseases: a Mendelian randomization study.

Jin Y, Yu X, Li J, Su M, Li X Front Immunol. 2024; 14:1319127.

PMID: 38193081 PMC: 10772142. DOI: 10.3389/fimmu.2023.1319127.


NSAID prescribing and adverse outcomes in common infections: a population-based cohort study.

Stuart B, Venekamp R, Hounkpatin H, Wilding S, Moore M, Little P BMJ Open. 2024; 14(1):e077365.

PMID: 38171621 PMC: 10773344. DOI: 10.1136/bmjopen-2023-077365.


A Retrospective Chart Review of Pediatric Complicated Community-Acquired Pneumonia: An Experience in the Al Qassimi Women and Children Hospital.

Yavuz S, Sherif A, Amirrad M, Sabet K, Hassan M, Abuelreish M Cureus. 2022; 14(11):e31119.

PMID: 36382327 PMC: 9636560. DOI: 10.7759/cureus.31119.


The Effect of CT-Guided Artificial Pneumothorax plus Thoracoscopy and Central Venous Catheterization on the Drainage Effect of Pediatric Empyema and Pulmonary Function.

Liu X, Yang Y, Ma X, Wang X, Ma B, Li S Contrast Media Mol Imaging. 2022; 2022:8230212.

PMID: 36110977 PMC: 9448614. DOI: 10.1155/2022/8230212.


References
1.
Thompson P, Gilbert R, Long P, Saxena S, Sharland M, Wong I . Effect of antibiotics for otitis media on mastoiditis in children: a retrospective cohort study using the United kingdom general practice research database. Pediatrics. 2009; 123(2):424-30. DOI: 10.1542/peds.2007-3349. View

2.
Rinaldo J, Pennock B . Effects of ibuprofen on endotoxin-induced alveolitis: biphasic dose response and dissociation between inflammation and hypoxemia. Am J Med Sci. 1986; 291(1):29-38. DOI: 10.1097/00000441-198601000-00007. View

3.
Byington C, Spencer L, Johnson T, Pavia A, Allen D, Mason E . An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis. 2002; 34(4):434-40. DOI: 10.1086/338460. View

4.
Light R . A new classification of parapneumonic effusions and empyema. Chest. 1995; 108(2):299-301. DOI: 10.1378/chest.108.2.299. View

5.
Grijalva C, Zhu Y, Nuorti J, Griffin M . Emergence of parapneumonic empyema in the USA. Thorax. 2011; 66(8):663-8. PMC: 4820002. DOI: 10.1136/thx.2010.156406. View